Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
- 1 January 2015
- journal article
- research article
- Published by Elsevier BV in Social Science & Medicine
- Vol. 124, 39-47
- https://doi.org/10.1016/j.socscimed.2014.11.003
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task ForceValue in Health, 2013
- Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying conceptsBMC Health Services Research, 2011
- What principles should govern the use of managed entry agreements?International Journal of Technology Assessment in Health Care, 2011
- Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturersHealth Policy, 2010
- Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providersAnnals of Oncology, 2010
- Access with Evidence Development SchemesPharmacoEconomics, 2010
- Funding the UnfundablePharmacoEconomics, 2010
- Canʼt Get No Satisfaction? Will Pay for Performance Help?PharmacoEconomics, 2010
- The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the futureBMC Neurology, 2009
- Price Differentiation and Transparency in the Global Pharmaceutical MarketplacePharmacoEconomics, 2005